SOURCE: Protherics PLC

April 10, 2007 13:05 ET

Protherics PLC announces Blocklisting Interim Review

Cheshire, UK -- (MARKET WIRE) -- April 10, 2007 --

                                 Protherics PLC

                         6 monthly Block Listing Return
                         Unapproved Share Option Scheme

London, UK; Brentwood, TN, US: 10 April 2007 - Protherics PLC ("Protherics" or
the "Company"), the international biopharmaceutical company focused on critical
care and cancer, announces that, today, the following 6 monthly block listing
return in respect of the Company's Unapproved Share Option Scheme has been
lodged with the FSA in accordance with Listing Rule 3.5.6.

Name of applicant:                                        Protherics PLC

Name of scheme:                                           Protherics PLC Unapproved Share Option Scheme

Period of return:                          From:          9 October 2006         To:       8 April 2007

Balance under scheme from previous return:                3,282,817

The amount by which the block scheme has been increased,  Nil
if the scheme has been increased since the date of the
last return:

Number of securities issued/allotted under scheme during  130,870

Balance under scheme not yet issued/allotted at end of    3,151,947

Number and class of securities originally listed and the  4,559,122 Ordinary Shares (date of admission: 8 April
date of admission                                         2005)

Total number of securities in issue at the end of the        
period                                                    339,169,625

                                   |  Ends  |

For further information please contact:

Nick Staples, Director of Corporate Affairs                +44 (0) 7919  480510
Julie Vickers, Company Secretary                             +44 (0)1928 518000

Financial Dynamics - press enquiries
London: Ben Atwell, Anna Keeble                            +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt                         +1 212 850 5600

Or visit

                      This information is provided by RNS
            The company news service from the London Stock Exchange